Form 4: Apellis CPO Kelley Boucher Granted 30,146 RSUs

Apellis Pharmaceuticals' Chief People Officer, Kelley Boucher, received a grant of 30,146 Restricted Stock Units, vesting over four years.

Summary

• Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 30,146 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on January 28, 2026.
• The RSUs were granted at a price of $0, which is typical for such awards.
• Following this transaction, Boucher beneficially owns 127,804 shares.
• The RSU award vests 25% annually over four years from the grant date, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. It reflects standard executive compensation practices and aligns management incentives with long-term shareholder value, without indicating any immediate operational or financial shifts.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief People Officer aligns management's long-term interests with those of shareholders.
• This compensation structure incentivizes continued service and performance over a four-year period.

Future Outlook

The Restricted Stock Units (RSUs) vest 25% annually over four years, indicating an expectation of continued service from Kelley Boucher through January 2030.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their compensation with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The structure of the RSU grant, with a four-year annual vesting schedule, is a standard compensation practice widely observed across the biotech and broader corporate sectors.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar long-term incentive plans for their executives to foster retention and performance alignment.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief People Officer's financial interests with long-term shareholder value, potentially fostering greater commitment to company performance.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Kelley Boucher's continued service to Apellis Pharmaceuticals for the RSUs to vest according to the 25% annual schedule over four years.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Kelley Boucher, Chief People Officer, Restricted Stock Units, RSU, Insider Transaction, Equity Grant, Compensation, Form 4